ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
7.94
-0.01 (-0.13%)
At close: Apr 28, 2026, 4:00 PM EDT
7.99
+0.05 (0.63%)
After-hours: Apr 28, 2026, 4:54 PM EDT
ARS Pharmaceuticals Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for ARS Pharmaceuticals stock has a target of 40, which predicts an increase of 403.78% from the current stock price of 7.94.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 4, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for ARS Pharmaceuticals is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth Capital | Roth Capital | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +403.78% | Sep 4, 2025 |
| Scotiabank | Scotiabank | Buy Initiates $30 | Buy | Initiates | $30 | +277.83% | Mar 7, 2025 |
| Raymond James | Raymond James | Strong Buy Maintains $26 → $28 | Strong Buy | Maintains | $26 → $28 | +252.64% | Jan 14, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $26 → $27 | Buy | Maintains | $26 → $27 | +240.05% | Jan 13, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +277.83% | Oct 8, 2024 |
Financial Forecast
Revenue This Year
157.94M
from 84.28M
Increased by 87.40%
Revenue Next Year
286.89M
from 157.94M
Increased by 81.64%
EPS This Year
-1.59
from -1.74
EPS Next Year
-0.68
from -1.59
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 190.7M | 343.9M | ||||||
| Avg | 157.9M | 286.9M | ||||||
| Low | 131.6M | 199.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 126.3% | 117.7% | ||||||
| Avg | 87.4% | 81.6% | ||||||
| Low | 56.1% | 26.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | -1.30 | -0.23 | |||||
| Avg | -1.59 | -0.68 | |||||
| Low | -1.76 | -1.23 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | - | - | |||||
| Avg | - | - | |||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.